Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review |
| |
| Authors: | Bowles Daniel W Flaig Thomas W |
| |
| Affiliation: | a Department of Medicine, University of Colorado School of Medicine, Denver, Colorado, USAb Department of Medicine, Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, Colorado, USA |
| |
| Abstract: | Background: Mitoxantrone, a topoisomerase II-targeted drug, is used to treat several conditions and is a Food and Drug Administration approved chemotherapeutic agent for the treatment of advanced carcinoma of the prostate. Case Report: A 64-year-old male with high-risk prostate cancer was treated with adjuvant mitoxantrone (12 mg/meter2) every 3 weeks for 6 cycles. Approximately 10 months after finishing therapy, he was diagnosed with an inv [16] Acute Myelogenous Leukemia (AML). Despite aggressive treatment and support, the patient had a rapidly fatal clinical course. Conclusion: Despite its regular use in this setting, this is the first reported case of treatment-associated AML after mitoxantrone in prostate cancer. |
| |
| Keywords: | Mitoxantrone Prostatic neoplasms Acute myelogenous leukemia Secondary leukemia |
| 本文献已被 InformaWorld PubMed 等数据库收录！ |
|
